BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Y, Zhang Z, Hong J, Liu W, Lu H, Du Y, Wang W, Xu J, Wang X, Huo L, Zhang G, Lan C, Li X, Li Y, Wang H, Zhang G, Zhu Y, Shu X, Chen Y, Wang J, Lu N; the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018;23:e12496. [DOI: 10.1111/hel.12496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, Chen X, Li X, Tang Y, Li X, Hao Q, Liu J, Sang T, Bo Y, Bai F. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother 2022;:e0218821. [PMID: 35652644 DOI: 10.1128/aac.02188-21] [Reference Citation Analysis]
2 Fu L, Xie C. A lucid review of Helicobacter pylori-induced DNA damage in gastric cancer. Helicobacter 2019;24:e12631. [PMID: 31295756 DOI: 10.1111/hel.12631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Wang G, Pang J, Hu X, Nie T, Lu X, Li X, Wang X, Lu Y, Yang X, Jiang J, Li C, Xiong YQ, You X. Daphnetin: A Novel Anti-Helicobacter pylori Agent. Int J Mol Sci 2019;20:E850. [PMID: 30781382 DOI: 10.3390/ijms20040850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
4 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Miftahussurur M, Aftab H, Shrestha PK, Sharma RP, Subsomwong P, Waskito LA, Doohan D, Fauzia KA, Yamaoka Y. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control 2019;8:40. [PMID: 30815255 DOI: 10.1186/s13756-019-0482-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Song C, Qian X, Zhu Y, Shu X, Song Y, Xiong Z, Ye J, Yu T, Ding L, Wang H, Lu N, Xie Y. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019. [DOI: 10.1111/hel.12591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Ji CR, Liu J, Li YY, Guo CG, Qu JY, Zhang Y, Zuo X. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020;10:e037375. [PMID: 33077561 DOI: 10.1136/bmjopen-2020-037375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gao C, Du SY, Fang L, Fan YH, Song AP, Chen H. Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance. Infect Drug Resist 2020;13:69-79. [PMID: 32021321 DOI: 10.2147/IDR.S232169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
9 Luo Z, Chen W, Shen X, Qin G, Yuan J, Hu B, Lyu J, Wen C, Xu W. Head and neck osteosarcoma: CT and MR imaging features. Dentomaxillofac Radiol 2020;49:20190202. [PMID: 31642708 DOI: 10.1259/dmfr.20190202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]